跳至主要内容
临床试验/NCT02452177
NCT02452177Unknown不适用

Preventive and Reversional Effect of Vitamin D on Parenteral Nutrition Associated Liver Disease: Clinical Observation and Experimental Study

Shengxian Fan1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2015年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
30
试验地点
1
主要终点
liver function

研究概览

简要总结

Patients who accept long-term parenteral nutrition tend to suffer from liver injury. The mechanism for this injury has two possible explanations. The first possible reason is intrinsic toxic effects of parenteral nutrition. The second is the basic pathological condition of intestinal failure which includes infection, bacterial translocation, etc. Cholestasis is the lethal presentation of this kind of liver disease. Farnesoid X receptor (FXR) is a member of ligand-activated nuclear receptor superfamily. FXR serves as a sensor for bile acids and promotes enterohepatic clearance of bile acids by controlling the expression of genes involved in their transport and metabolism. Considering the activation of vitamin D receptor (VDR) by vitamin D can induce FXR-related genes in the liver.The hypothesis of this study is that vitamin D plays a key role in the prevention and reversion of the liver via VDR and/or FXR signaling pathway. Using a mouse cholestasis model based on short bowel syndrome and parenteral nutrition, the researchers will investigate the dynamic change of plasma vitamin D level. Afterward, intravenous supplement of vitamin D was added to this model to demonstrate vitamin D can ameliorate cholestasis. An in vitro system was developed to investigate the importance of FXR signaling pathway in this effect.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Single (Participant)

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with short bowel syndrome supported by total parenteral nutrition.
  • Patients have intestine more than 50cm.
  • Requirements of informed consent and assent of participant, parent or legal guardian as applicable consciousness and ability cooperate.

排除标准

  • Patients have obstruction of biliary tract, infection, autoimmune disease, cancer.
  • Patients have intestine less than 50cm.
  • A clinically significant laboratory abnormality or a history of significant cardiac, pulmonary, hepatic, or renal disease.
  • Female with positive pregnancy.
  • Allergy to ursodeoxycholic acid.

研究组 & 干预措施

Vitamin D

Experimental

Patients in this group were treated with oral vitamin D at a dose of 1200 IU per day for 2 months.

干预措施: Vitamin D (Drug)

结局指标

主要结局

liver function

时间窗: two months

Serum aspartate aminotransferase, alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), triglyceride, very low density lipoprotein (VLDL), and bilirubin (total, direct, and indirect) were analyzed

次要结局

未报告次要终点

研究者

发起方
Shengxian Fan
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Shengxian Fan

M.D.

Jinling Hospital, China

研究点 (1)

Loading locations...

相似试验